It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Diabetic wound healing, including diabetic foot ulcer (DFU), is a serious complication of diabetes. Considering the complexity of DFU development, the identification of a factor that mediates multiple pathogeneses is important for treatment. In this study, we found that CXXC-type zinc finger protein 5 (CXXC5), a negative regulator of the Wnt/β-catenin pathway, was overexpressed with suppression of the Wnt/β-catenin pathway and its target genes involved in wound healing and angiogenesis in the wound tissues of DFU patients and diabetes-induced model mice. KY19334, a small molecule that activates the Wnt/β-catenin pathway by inhibiting the CXXC5-Dvl interaction, accelerated wound healing in diabetic mice. The enhancement of diabetic wound healing could be achieved by restoring the suppressed Wnt/β-catenin signaling and subsequently inducing its target genes. Moreover, KY19334 induced angiogenesis in hindlimb ischemia model mice. Overall, these findings revealed that restorative activation of Wnt/β-catenin signaling by inhibiting the function of cytosolic CXXC5 could be a therapeutic approach for treating DFUs.
Diabetes: A road to recovery of long-lasting foot ulcers
Drugs that alleviate a molecular blockade against wound healing and vessel growth could offer effective therapies for diabetic foot ulcers (DFU). Such chronic wounds are a serious consequence of type 2 diabetes, and current therapies only manage the symptoms without providing recovery. Researchers led by Kang-Yell Choi of Yonsei University, Seoul, South Korea, have determined that DFU from human patients and animal models exhibit elevated levels of CXXC5, a protein that inhibits genes associated with healing and angiogenesis. Treatment with an agent that selectively blocks CXXC5 function reversed this inhibition in two different mouse models, accelerating both wound repair and the formation of new blood vessels. The latter is thought to be an especially important aspect of DFU recovery, suggesting that this treatment approach could give long-lasting relief to patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Yonsei University, Department of Biotechnology, College of Life Science and Biotechnology, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
2 Yonsei University College of Medicine, Department of Orthopedic Surgery, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
3 Yonsei University College of Medicine, Department of Orthopedic Surgery, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); Yonsei University College of Medicine, Brain Korea 21 PLUS Project for Medical Science, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454)
4 Yonsei University, Department of Biotechnology, College of Life Science and Biotechnology, Seoul, South Korea (GRID:grid.15444.30) (ISNI:0000 0004 0470 5454); CK Regeon Inc, Seoul, South Korea (GRID:grid.15444.30)